Labcorp EVP gets shares from RSU vesting, tax withholding

Labcorp Holdings Inc. executive Akinbolade Oyegunwa, EVP, CIO & CTO, reported routine equity compensation activity.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Akinbolade Oyegunwa, EVP, CIO & CTO, reported routine equity compensation activity. On February 6 and 7, 2026, restricted stock units (RSUs) covering 180 and 149 shares of common stock, respectively, were converted into Labcorp common shares.

To cover tax withholding obligations, a total of 112 common shares were withheld, at prices of $277.2 and $274.01 per share. Following these transactions, Oyegunwa directly held 3,944.253 shares of common stock and 1,610 RSUs, each RSU representing the right to receive one share of common stock as they vest over the disclosed schedules.

Insider Trade Summary

329 shares exercised/converted

Exercise 6 txns

Insider Oyegunwa Akinbolade

Role EVP, CIO & CTO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	51	$274.01	$14K
Exercise	Restricted Stock Unit	149	$0.00	$0.00
Exercise	Common Stock	149	$0.00	$0.00
Exercise	Restricted Stock Unit	180	$0.00	$0.00
Exercise	Common Stock	180	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	61	$277.20	$17K

Holdings After Transaction: Restricted Stock Unit — 1,610 contracts (Direct); Common Stock — 3,944.253 shares (Direct)

Footnotes (5)

F1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
F2. Stock withholding to satisfy tax withholding obligations.
F3. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.
F4. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
F5. The Restricted Stock Units vested in two equal installments beginning on February 7, 2025 and are now fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Labcorp (LH) EVP Akinbolade Oyegunwa report?

Oyegunwa reported routine equity compensation activity involving vested restricted stock units converting into Labcorp common shares. Some shares were withheld to satisfy tax obligations, and his direct holdings of both common stock and RSUs were updated accordingly in the Form 4 filing.

How many Labcorp (LH) shares did Oyegunwa acquire from RSU vesting?

He acquired 180 common shares on February 6, 2026 and 149 common shares on February 7, 2026 through the vesting and settlement of restricted stock units. Each RSU represents the contingent right to receive one share of Labcorp common stock upon vesting.

How were taxes handled on Oyegunwa’s Labcorp (LH) RSU vesting?

Taxes were satisfied through share withholding. Labcorp withheld 61 common shares at $277.2 per share and 51 common shares at $274.01 per share, rather than requiring Oyegunwa to pay the tax withholding amount in cash.

What are Oyegunwa’s Labcorp (LH) common stock holdings after these transactions?

After the reported transactions, Oyegunwa directly held 3,944.253 shares of Labcorp common stock. This figure reflects the newly issued shares from vested RSUs, net of the shares withheld by the company to cover tax withholding obligations.

How many Labcorp (LH) restricted stock units does Oyegunwa hold after vesting?

Following the February 2026 vesting events, Oyegunwa held 1,610 restricted stock units. The filing notes this number reflects the aggregate RSUs still outstanding, each representing the contingent right to receive one share of Labcorp common stock upon future vesting.

What is the vesting schedule for Oyegunwa’s Labcorp (LH) RSUs?

One RSU grant vests in three equal annual installments beginning on February 6, 2025. Another RSU grant vested in two equal installments beginning on February 7, 2025 and is now fully vested, as disclosed in the filing’s explanatory footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/10/2026 - 03:15 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oyegunwa Akinbolade

(Last)

(First)

(Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON

27215

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, CIO & CTO

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/06/2026		M		180	A	⁽¹⁾	3,907.253	D
Common Stock	02/06/2026		F⁽²⁾		61	D	$277.2	3,846.253	D
Common Stock	02/07/2026		M		149	A	⁽¹⁾	3,995.253	D
Common Stock	02/09/2026		F⁽²⁾		51	D	$274.01	3,944.253	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	02/06/2026		M			180	⁽³⁾	⁽³⁾	Common Stock	180	$0	1,759⁽⁴⁾	D
Restricted Stock Unit	⁽¹⁾	02/07/2026		M			149	⁽⁵⁾	⁽⁵⁾	Common Stock	149	$0	1,610⁽⁴⁾	D

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

2. Stock withholding to satisfy tax withholding obligations.

3. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.

4. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

5. The Restricted Stock Units vested in two equal installments beginning on February 7, 2025 and are now fully vested.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Akinbolade Oyegunwa	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR